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leuprorelide acetate depots of 3.75 mg subcutaneously, ev-
ery 4 weeks.  Results: At baseline, mean GH levels were com-
parable with those of controls, whereas IGF-I and IGFBP-3 
standard deviation scores (SDS) were significantly lower 
than zero SDS. After 3 months of GnRHa treatment, all boys 
showed clinical arrest of puberty. The area under the curve 
above zero, mean and maximum LH and FSH had significant-
ly decreased to prepubertal levels. Peak LH during the GnRH 
agonist test, however, indicated insufficient pubertal sup-
pression in 43% of boys. Overnight GH profile characteristics 
and IGF-I and IGFBP-3 levels did not significantly change. 
 Conclusions: Puberty was sufficiently suppressed by GnRHa 
treatment, as shown by the prepubertal LH and FSH profiles. 
After 3 months of GnRHa treatment, overnight GH profile 
characteristics had not significantly changed, reflecting that 
GH levels are comparable for prepubertal and early pubertal 
boys. 
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 Abstract 
 Aims: To evaluate if 3 months of gonadotropin-releasing 
hormone analogue (GnRHa) treatment results in sufficient 
suppression of pubertal luteinizing hormone (LH) and folli-
cle-stimulating hormone (FSH) profile patterns in short pu-
bertal small for gestational age (SGA) boys. To compare 
growth hormone (GH) profiles and fasting insulin-like growth 
factor (IGF)-I and IGF-binding protein-3 (IGFBP-3) levels after 
3 months of GnRHa treatment with those at baseline.  Meth-
ods: After measurement of baseline overnight profiles and 
IGF-I and IGFBP-3 levels, 14 short pubertal SGA boys received 
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 Introduction 
 Although catch-up growth occurs in most children 
born small for gestational age (SGA), about 10% of infants 
remain short throughout childhood and adulthood  [1, 2] . 
Persistent changes in the growth hormone (GH)/insulin-
like growth factor (IGF)/IGF-binding protein (IGFBP) 
axis might underlie this failure in catch-up growth  [3–7] . 
 In some short SGA children, puberty starts at a rela-
tively early age for their short stature, thereby compro-
mising adult height  [8, 9] . Postponement of puberty with 
gonadotropin-releasing hormone analogue (GnRHa) 
treatment was studied in boys with central precocious 
puberty, and most of these boys reached an adult height 
in the range of their genetic height potential  [10] .
 In healthy, older prepubertal boys, a very discrete day 
and night pulsatile secretion pattern of luteinizing hor-
mone (LH) and follicle-stimulating hormone (FSH) is de-
tectable  [11–13] . At the onset of puberty (G2), LH and FSH 
are secreted in a regular pattern during the daytime, with 
a further amplification during sleep. From early puberty 
onwards, increasing pulse frequency and pulse ampli-
tude with an obvious night/day rhythm was found  [11–
14] . 
 Data concerning spontaneous overnight LH and FSH 
profile patterns during GnRHa treatment are scarce. 
Therefore, our primary objective was to evaluate if
GnRHa treatment results in sufficient suppression of pu-
bertal LH and FSH profile patterns. Admitting children 
to a hospital in order to perform overnight LH and FSH 
profiles is not feasible in routine care. Therefore, all the 
boys in our study also underwent a GnRH agonist test 
during the morning after the second overnight profile. In 
the Netherlands, a consensus-based peak LH level below 
3 IU/l (peak LH GnRH ; 95th percentile of prepubertal peak 
LH response) with testosterone levels below 1 nmol/l 
 (upper limit of prepubertal values) during a GnRH ago-
nist test are used as cutoff levels for sufficient pubertal 
suppression  [15] . Our second objective was to evaluate in 
how many boys sufficient pubertal suppression is identi-
fied by the GnRH agonist test.
 A decrease in growth velocity is a well-known phe-
nomenon during GnRHa treatment  [16–19] . There are 
only limited data on spontaneous GH, IGF-I and IGFBP-
3 levels during GnRHa treatment  [20–22] . Notably, no 
data are available in short pubertal boys born SGA, either 
before or during GnRHa treatment. Therefore, our third 
objective was to determine overnight GH profiles and 
fasting levels of IGF-I and IGFBP-3, both before and after 
3 months of GnRHa treatment. 
 Subjects and Methods 
 Subjects 
 The study group comprised short boys born SGA who were at 
the beginning of puberty. They were included in a clinical trial 
investigating combined treatment with GnRHa and GH. All boys 
started GH treatment after 3 months of GnRHa treatment. Chil-
dren who met the following criteria were included: (1) birth length 
and/or birth weight standard deviation score (SDS) below –2 for 
gestational age  [23] , (2) chronological age of 8 years or older at the 
start of the study, (3) current height SDS below –2.5 or a predicted 
adult height less than –2.5 SDS (calculated as height at the start of 
puberty plus 30 cm, according to Dutch references  [24] ) and (4) 
early pubertal stage defined as a testicular volume of 4 ml or more, 
Tanner genital stage 2 or 3  [25] and a GnRH agonist test result 
with a peak LH of 10 IU/l or more, indicating central puberty  [26] . 
Children were excluded if they met one of the following criteria: 
(1) a complicated neonatal period with signs of severe asphyxia 
(defined as an Apgar score  ! 3 after 5 min), (2) long-term compli-
cations of respiratory ventilation such as bronchopulmonary dys-
plasia, (3) endocrine (including idiopathic GH deficiency) or met-
abolic disorders, chromosomal defects, growth failures caused by 
other disorders (such as emotional deprivation, severe chronic ill-
ness or achondroplasia) or syndromes (except for Silver-Russell 
syndrome) and (4) previous or present medication that could in-
terfere with growth or GH treatment. The study was approved by 
the Medical Ethics Committee of the participating centers, and 
written informed consent was obtained from parents or custodi-
ans and from subjects if aged 12 years or older.
 Study Design 
 Overnight LH, FSH and GH profiles were performed in 10 
boys, both before and after 3 months of GnRHa treatment (leu-
prorelide acetate   depots of 3.75 mg subcutaneously, every 4 weeks, 
with an interval of 14 days between the first 2 injections). Chil-
dren were admitted to the hospital and an indwelling venous 
catheter was inserted in an antecubital vein. For a period of 12 h 
(19.00–7.20 h), blood was taken every 20 min for determination of 
serum LH, FSH and GH levels. Children followed their normal 
eating and sleeping pattern. Sleep during both admissions was 
recorded by the same investigator (D.vdK.). All children went
to bed at 22.30 h, were asleep before 23.30 h and woke up around 
7.00 h the next morning. The time awake was comparable be-
tween both admissions. The next morning, a fasting blood sample 
was taken for measurement of IGF-I and IGFBP-3 levels. 
 Height was measured using a Harpenden stadiometer and ex-
pressed as SDS for calendar age  [24] . The same investigator (D.
vdK.) assessed pubertal stage according to Tanner during both 
visits, using an orchidometer  [25] . Bone age was assessed by one 
investigator (D.vdK.), using the segmented Greulich and Pyle ref-
erence  [27] . Fat mass for height at baseline was measured by dual-
energy X-ray absorptiometry  [28] . 
 The inhibition of gonadotropin secretion was checked the 
morning after the second overnight profile by a GnRH agonist 
test, as follows: 0.5 mg (0.5 ml) of leuprorelide acetate was inject-
ed subcutaneously, and after 3 h, a blood sample was taken for 
determination of LH, FSH and testosterone levels  [29, 30] . In the 
4 boys in whom overnight profiles were not performed, fasting 
IGF-I and IGFBP-3 levels and a GnRH agonist test were per-
formed during the second visit, after 3 months of GnRHa treat-
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ment. We compared our overnight GH profile results with those 
found by Rose et al.  [31] , who performed overnight GH profiles in 
healthy boys with normal stature and similar pubertal stage.
 Hormone Assays 
 Overnight LH and FSH levels were measured by chemilumi-
nescence-based immunometric methods (Immulite 2000, Diag-
nostic Products Corporation, Los Angeles, Calif., USA) using 
WHO preparations 80/552 and 78/549 as standards. Detection 
limits for both assays were 0.1 IU/l, and values below 0.1 IU/l were 
assigned the value 0.1 IU/l. Intra- and interassay coefficients of 
variation (CVs) were below 4 and 7%, respectively, for LH and be-
low 3 and 6%, respectively, for FSH. Testosterone levels were mea-
sured using a coated-tube radioimmunoassay obtained from Di-
agnostic Products Corporation. The detection limit for this assay 
is 0.1 nmol/l. Intra- and interassay CVs were below 6 and 8%, re-
spectively.
 Overnight GH levels were measured by an immunometric as-
say (Immulite 2000) with a lower detection limit of 0.13 mU/l. 
Values lower than 0.13 mU/l were assigned the value 0.13 mU/l. 
The results of low, medium and high standards [mean  8 intra-
assay standard deviation (SD) and  8 interassay SD, respectively] 
were 6.8  8 0.23 and  8 0.44, 14.0  8 0.47 and  8 0.75, and 44  8 
1.87 and  8 2.94 mU/l, respectively. Intra- and interassay CVs 
were, respectively, 3.5 and 6.5% at a level of 6.8 mU/l, 3.4 and 5.5% 
at a level of 14.0 mU/l and 4.2 and 6.6% at a level of 44 mU/l. Based 
on standard samples, our assay was comparable with the assay 
used by Kamp et al.  [20] , who measured GH levels by polyclonal 
radioimmunoassay with a detection limit of 0.5   g/l. Their re-
sults (mean  8 SD) of low, medium and high standards were 1.1 
 8 0.1, 3.6  8 0.4 and 16.9  8 2.0   g/l, respectively. Intra- and in-
terassay CVs were, respectively, 9.1 and 18.7% at a level of 1.2   g/l, 
3.7 and 16.6% at a level of 5.1   g/l and 3.1 and 9.0% at a level of 
18.5   g/l. A conversion factor of 2.6 was used to transform data 
from micrograms per liter to milliunits per liter  [32] .
 Serum IGF-I and IGFBP-3 levels were measured in one labora-
tory using a specific radioimmunoassay  [33] . Serum levels were 
expressed as SDS to adjust for age and sex  [34] . The intra- and in-
terassay CVs were 4 and 6%, respectively. 
 Reported LH Profiles for Prepubertal Boys 
 Prepubertal boys with a testicular volume of 1–2 ml have a very 
discrete nighttime pulsatile pattern of gonadotropin secretion 
with mean ( 8 SEM) LH levels of 0.27  8 0.15 IU/l and maximum 
LH levels of 1.06  8 0.24 IU/l. Mean and maximum LH levels in-
creased to 1.34  8 0.42 and 3.70  8 1.21 IU/l, respectively, in pre-
pubertal boys with a testicular volume of 3 ml  [12] . 
 Calculations 
 The area under the curve above zero (AUC 0 ) of LH and FSH 
profile patterns was calculated by the trapezoidal method. Over-
night GH profiles were analyzed using the Pulsar program  [33, 
35] .
 Statistics 
 Because of a non-Gaussian-shaped distribution, data were ex-
pressed as medians (interquartile range in parentheses). The 
Mann-Whitney test was used for differences between groups. The 
Wilcoxon signed rank test was used to determine differences be-
tween points in time within groups. SDS were compared with 
zero SDS using   2 tests. To analyze night-to-night variation, cor-
relation coefficients were calculated between individual time 
points for an individual patient. The calculated coefficients were 
analyzed using   2 tests. Spearman’s correlation coefficient was 
used for correlations. A p value  ! 0.05 was considered significant. 
Analyses were performed using the computer statistical package 
SPSS (version 11) for Windows.
 Results 
 Clinical Characteristics 
 Table 1 shows the clinical data of all subjects. After 3 
months of GnRHa treatment, none of the boys showed 
clinical progression of puberty and 2 boys showed clini-
cal regression of puberty.
 Overnight LH and FSH Profiles  
 Baseline. Characteristics of baseline overnight LH and 
FSH profiles are shown in  table 2 . 
 After 3 Months of GnRHa Treatment. Characteristics 
of overnight LH and FSH profiles after 3 months of
GnRHa treatment are shown in  table 2 . AUC 0 , mean and 
maximum LH and FSH levels had significantly decreased 
to very low levels. Mean LH levels were 0.41 IU/l and 
maximum LH levels were 0.72 IU/l, whereas mean FSH 
levels were 0.21 IU/l and maximum FSH levels were 0.38 
IU/l. Thus, none of the boys had a pubertal pulsatile pat-
tern ( fig. 1 ,  2 ).
 GnRH Agonist Test. After 3 months of GnRHa treat-
ment, peak LH GnRH was below 3 IU/l, with testosterone 
levels below 1 nmol/l in 8 out of 14 boys. Peak LH GnRH 
Table 1. Clinical characteristics before the start of GnRHa treat-
ment
Number of boys 14
Gestational age, weeks 39.0 (37.4–40.0)
Birth weight SDS –1.9 (–2.2 to –1.6)
Birth length SDS –2.4 (–2.8 to –2.1)
At start of GnRHa treatment
Genital stage 2, n 12
Genital stage 3, n 2
Age, years 12.7 (12.2–12.9)
Bone age, years 12.1 (11.2–12.6)
Height SDS –2.5 (–3.4 to –2.2)
Weight SDS –2.7 (–3.4 to –1.3)
Fat mass SDS –0.5 (–1.4 to –0.08)
Data are expressed as medians (interquartile range in paren-
theses).
 LH, FSH and GH Levels during GnRHa 
Treatment in Short SGA Boys 
Horm Res 2009;71:260–267 263
varied between 3.3 and 5.2 IU/l in 6 boys (43%). Testos-
terone levels were below 1 nmol/l in all 6 boys, and none 
of these boys showed clinical progression. No significant 
differences in LH and FSH profiles were found between 
boys with a peak LH GnRH above or below 3 IU/l. Testos-
terone levels had significantly decreased from 6.5 (1.3–
9.9) nmol/l to 0.25 (0.10–0.53) nmol/l (p = 0.001) after 3 
months of GnRHa treatment. No significant differences 
in testosterone levels were found between boys with a 
peak LH GnRH above or below 3 IU/l. 
 Correlations between LH Profiles and the GnRH Agonist 
Test. At baseline, mean LH levels during the LH profile cor-
related positively with testosterone levels during the GnRH 
agonist test (r = 0.67, p = 0.03). Maximum LH levels during 
the LH profile correlated positively with peak LH GnRH 
(r = 0.69, p = 0.03). After 3 months of GnRHa treatment, 
no correlations were found between characteristics of the 
LH profiles and peak LH or testosterone levels during the 
GnRH agonist test. Peak LH GnRH and peak FSH GnRH at 
baseline correlated respectively with peak LH GnRH and 
peak FSH GnRH after 3 months of GnRHa treatment (r = 
0.73, p = 0.003 and r = 0.70, p = 0.006, respectively). 
 Overnight GH Profiles and IGF-I and IGFBP-3 Levels 
 Baseline. Characteristics of the overnight GH profiles 
and IGF-I and IGFBP-3 levels at baseline are listed in  ta-
ble 3 . Mean GH levels in boys with genital stage 2 were 
comparable with mean GH levels found in boys with nor-
mal stature and similar genital stage. Since only 2 boys 
had genital stage 3, a comparison with boys with normal 
stature and similar pubertal stage was not feasible. IGF-I 
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 Fig. 1. Representative examples of individual overnight LH pro-
files in 4 boys, performed at baseline ( X ) and after 3 months of 
GnRHa treatment ( j ). Subjects A, B and C were genital stage 2, 
while subject D was genital stage 3. The results of the GnRH ago-
nist test performed after 3 months of GnRHa treatment are shown 
in the insets. m = Months. 
Table 2. Characteristics of overnight LH and FSH profiles, at 
baseline and after 3 months of GnRHa treatment
Baseline 3 months p value
Overnight LH profiles
AUC0 LH, IU/l ! 12 h 36.0 (18.1–52.1) 5.2 (3.7–8.3) 0.005
Mean LH, IU/l 2.8 (1.4–4.1) 0.41 (0.29–0.66) 0.005
Maximum LH, IU/l 7.3 (4.3–9.7) 0.72 (0.43–0.92) 0.005
Overnight FSH profiles
AUC0 FSH, IU/l ! 12 h 21.0 (11.3–63.7) 2.7 (1.5–5.3) 0.005
Mean FSH, IU/l 1.7 (0.89–5.0) 0.21 (0.12–0.42) 0.005
Maximum FSH, IU/l 4.0 (1.6–6.3) 0.38 (0.22–0.93) 0.005
GnRH agonist test
Peak LH, IU/l 32.4 (14.1–43.1) 2.8 (2.1–4.0) 0.001
Peak FSH, IU/l 7.2 (4.3–11.8) 0.65 (0.40–1.1) 0.001
Testosterone, nmol/l 6.5 (1.3–9.9) 0.25 (0.10–0.53) 0.001
Data are expressed as medians (interquartile range in parentheses). Re-
ported mean prepubertal values for mean and maximum LH levels are 
0.27–1.3 and 1.1–3.7 IU/l, respectively. p values are calculated compared to 
baseline.
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and IGFBP-3 levels were significantly lower than zero 
SDS (p = 0.03 and p = 0.001, respectively). 
 After 3 Months of GnRHa Treatment.  Characteristics 
of overnight GH profiles, IGF-I and IGFBP-3 levels after 
3 months of GnRHa treatment are listed in  table 3 . No 
significant differences were found between GH profile 
characteristics at baseline and after 3 months of GnRHa 
treatment. Mean GH levels remained comparable with 
those found in controls.  Figure 3 shows that there was a 
wide interindividual variation in mean serum GH levels, 
both at baseline and after 3 months of GnRHa treatment. 
IGF-I and IGFBP-3 levels did not significantly change 
and SDS values remained significantly lower than zero 
Table 3. Characteristics of overnight GH, IGF-I and IGFPB-3 lev-
els, at baseline and after 3 months of GnRHa treatment
Baseline 3 months p 
value
AUC0, mU/l ! 12 h 135 (92.1–263) 130 (70.0–238) 0.6
Mean GH, mU/l 10.8 (7.3–20.8) 10.4 (5.6–18.8) 0.6
Maximum GH, mU/l 46.2 (32.8–137.8) 55.3 (30.9–89.7) 0.4
Pulse amplitude, mU/l 16.4 (13.7–32.5) 22.8 (11.6–32.7) 0.4
Number of GH peaks >10 
mU/l 3.5 (2.8–5.0) 4.0 (3.0–4.0) 1.0
IGF-I SDS –0.8 (–1.5 to –0.04)a –0.9 (–1.4 to –0.2)a 0.6
IGFBP-3 SDS –1.0 (–1.5 to –0.6)b –1.2 (–1.7 to –0.7)b 0.1
Data are expressed as medians (interquartile range in parentheses).
p values calculated comparing data at 3 months to those at baseline.
a p ≤ 0.05 compared to zero SDS; b p ≤ 0.001 compared to zero SDS.
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 Fig. 3. Mean GH levels for each subject during overnight GH pro-
files, at baseline (open bars) and after 3 months of GnRHa treat-
ment (solid bars). 
 Fig. 2. Representative examples of individual overnight FSH pro-
files in the same 4 boys as shown in figure 1, performed at baseline 
( X ) and after 3 months of GnRHa treatment ( j ). Subjects A, B and 
C were genital stage 2, while subject D was genital stage 3. The 
results of the GnRH agonist test performed after 3 months of
GnRHa treatment are shown in the insets. m = Months. 
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SDS (p = 0.03 and p  ! 0.001, respectively). In all boys, 
there was a significant correlation between the timing of 
GH peaks at baseline and after 3 months of GnRHa treat-
ment (r = 0.4, p = 0.01). 
 Correlations between GH Profiles, Clinical Character-
istics and the GnRH Agonist Test.  Neither at baseline nor 
after 3 months of GnRHa treatment were correlations 
found between characteristics of the overnight GH pro-
files and age, height SDS, peak LH GnRH , bone age (at base-
line) or fat mass SDS (at baseline).
 Correlations between GH Profiles and IGF-I and IGFBP-
3 Levels. At baseline, mean GH levels correlated signifi-
cantly with IGF-I SDS (r = 0.72, p = 0.02). After 3 months 
of GnRHa treatment, mean GH levels correlated signifi-
cantly with IGF-I SDS (r = 0.76, p = 0.01) and IGFBP-3 
SDS (r = 0.64, p = 0.048). Maximum GH levels correlated 
significantly with IGF-I SDS (r = 0.69, p = 0.03).
 Discussion 
 In the present study, LH and FSH levels had signifi-
cantly decreased to prepubertal levels in all boys, show-
ing that treatment with leuprorelide acetate depots of 3.75 
mg subcutaneously every 4 weeks resulted in an adequate 
suppression of puberty. The GnRH agonist test performed 
after 3 months of GnRHa treatment falsely indicated in-
sufficient pubertal suppression in 43% of the boys. No 
significant changes in overnight GH profile characteris-
tics and IGF-I and IGFBP-3 SDS were found after 3 
months of GnRHa treatment, compared to baseline.
 Overnight LH and FSH Profiles 
 After 3 months of GnRHa treatment, all boys had clin-
ical arrest of puberty and 2 boys had clinical regression 
of puberty. AUC 0 , mean and maximum LH and FSH lev-
els had significantly decreased to very low levels. The pat-
tern of LH and FSH profiles after 3 months of GnRHa 
treatment in short boys born SGA was similar to prepu-
bertal profiles found in healthy boys  [12] . 
 Overnight LH and FSH profiles were performed for 
research purposes since admitting children to a hospital 
in order to perform overnight profiles is not suitable for 
routine clinical care. After 3 months of GnRHa treat-
ment, peak LH GnRH was above the cutoff level of 3 IU/l in 
43% of the boys  [15] . Notably, all boys had prepubertal 
testosterone levels (below 1 nmol/l). Furthermore, no sig-
nificant differences in LH and FSH profiles were found 
between boys with a peak LH GnRH above or below 3 IU/l. 
Our findings are in agreement with the only comparable 
study, performed in 6 children (2 boys) with central pre-
cocious puberty  [36] . In this study, children who had clin-
ically well suppressed puberty had LH levels similar to 
prepubertal children. 
 Peak LH GnRH was known before LH levels during the 
overnight profiles were available. The schedule of leupro-
relide acetate depot injections was changed to every
3 weeks instead of every 4 weeks in boys with a peak
LH GnRH above 3 IU/l, according to Dutch consensus 
guidelines. This adjustment seemed to be unnecessary 
once we received the results of the overnight LH profiles.
 Although we found prepubertal LH profiles in all boys 
after 3 months of GnRHa treatment, LH and FSH profiles 
were determined in a rather small group. In order to de-
termine which peak LH GnRH cutoff level indicates suffi-
cient pubertal suppression, we recommend future research 
in a larger study group, including boys and girls with dif-
ferent pubertal stages and with sufficient and insufficient 
pubertal suppression according to their LH profiles. 
 Overnight GH Profiles, IGF-I and IGFBP-3 Levels 
 To our knowledge, this is the first study describing 
baseline GH profiles in short pubertal boys born SGA. 
We found normal mean GH levels, compared to boys 
with normal stature and similar pubertal stage  [20] . 
Overnight GH profiles have been performed in prepu-
bertal short SGA children with conflicting results. Some 
authors reported significantly lower levels in short chil-
dren born SGA, compared to healthy children born ap-
propriate for gestational age  [3, 4] , whereas others found 
comparable mean GH levels  [37] . The wide variability in 
and overlap between GH secretion seen in SGA cohorts 
and control populations are consistent phenomena  [3, 4, 
20, 37] . Within the heterogeneous SGA population, this 
probably reflects a continuum in GH secretion, ranging 
from GH deficiency to normal GH secretion. Alterations 
in the GH/IGF/IGFBP pathway and genetic variations 
found in genes involved in this pathway  [38, 39] might in 
part explain this continuum. 
 Baseline IGF-I and IGFBP-3 SDS were significantly 
lower than zero SDS, which is in line with previous stud-
ies describing low IGF-I and IGFBP-3 levels throughout 
childhood in subjects born SGA  [6, 40, 41] . IGF-I SDS was 
significantly correlated with mean GH levels, both at 
baseline and after 3 months of GnRHa treatment, and 
IGFBP-3 SDS was significantly correlated with mean GH 
levels after 3 months of GnRHa treatment. IGF-I and 
IGFBP-3 levels were found to reflect GH secretion in 
healthy children  [42] . Our study shows that this reflec-
tion is also applicable for short boys born SGA. 
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 After 3 months of GnRHa treatment, we found no sig-
nificant changes in AUC 0 , mean and maximum GH lev-
els compared to baseline. Likewise, IGF-I and IGFBP-3 
levels had not significantly changed. Rose et al.  [31] 
showed that mean GH levels in healthy boys with testicu-
lar volumes between 5 and 10 ml remained near prepu-
bertal levels, whereas a significant increase in spontane-
ous GH and IGF-I levels was found when Tanner stage 3 
was reached. In our study, all boys in whom overnight 
GH profiles were performed had testicular volumes be-
tween 4 and 8 ml. Thus, this could well explain why we 
did not find significant changes in GH and IGF-I levels 
after 3 months of GnRHa treatment. 
 We found a significant trend in the timing of GH 
peaks within the same individual. The reproducibility of 
measurements of overnight GH secretion was reported to 
be superior to that of provocative tests  [32] . The intrain-
dividual reproducibility was found to be less profound 
 [43] .  Our results indicate the existence of an intrinsic 
rhythm regulating endogenous GH secretion in individ-
ual subjects. 
 In conclusion, treatment with leuprorelide acetate de-
pots of 3.75 mg every 4 weeks results in an effective inhi-
bition of central puberty, as shown by prepubertal over-
night LH and FSH secretion patterns and clinical signs of 
pubertal arrest. The GnRH agonist test falsely indicated 
insufficient pubertal suppression in almost half of the 
boys, resulting in unnecessary adjustments in the fre-
quency of depot injections. Low IGF-I and IGFBP-3 levels 
were found at the start of puberty, although mean GH 
levels were normal for pubertal stage. Parameters of the 
overnight GH profile did not significantly change after 3 
months of GnRHa treatment, consistent with GH levels 
being comparable for prepubertal and early pubertal 
boys.
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